Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

CompletedOBSERVATIONAL

Enrollment

369,600

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

December 11, 2020

Study Completion Date

December 11, 2020

Conditions

Age-related Macular Degeneration (AMD)

Interventions

OTHER

Aflibercept

intravitreal injection

OTHER

Ranibizumab

intravitreal injection

OTHER

Bevacizumab

intravitreal injection

Trial Locations (1)

Novartis Investigative Site, East Hanover